Rabeximod is a well-tolerated, orally available Phase 2 drug candidate that selectively targets the inflammatory macrophage - the central orchestrator of the inflammatory process. Rabeximod is currently being developed as a potential treatment of rheumatoid arthritis and moderate Covid-19, two diseases that are driven by harmful inflammatory processes.

Rabeximod already has a broad patent portfolio on several key markets. The new patent application on Rabeximod includes composition of matter claims that strengthen the protection for its therapeutic use across several indications and offer patent protection until 2043 or longer. The applications have been filed with patent authorities in Cyxone's key markets and will be made publicly available 18 months after filing.

"Cyxone has continuously ramped up its scientific activities - seeking new insights into the novel mode of action of Rabeximod and improving the drug material. Our lead candidate's unique mode of action, proven safety profile, and potential to be developed as a therapeutic in multiple indications suggests a significant potential commercial value. Our ambition to establish an even more robust patent portfolio is therefore of vital importance, both to protect our asset, but also in order to attract potential commercial partners," comments Tara Heitner, CEO, Cyxone.

Contact

Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se.For more information, please visit www.cyxone.com